GSK3B and hepatocellular carcinoma: In addition, GSK3B has been shown to be aberrantly activated in HCC, and its high expression is closely associated with a poor prognosis of HCC patients [72], which is in agreement with our data showing a similar phenomenon for hMT3 in particular for subjects treated with sorafenib.